Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 6/20 | 0.50 |
| ▸ | OXTR | P30559 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4944443 | 1.00 | AGTR2 (0.50) | AGTR2OXTRALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4944440 | 1.00 | AGTR2 (0.50) | AGTR2OXTRALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4942624 | 0.89 | AGTR2 (0.46) | AGTR2OXTRALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4942629 | 0.89 | AGTR2 (0.46) | AGTR2OXTRALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4936068 | 0.89 | OXTR (0.56) | AGTR2OXTRAGTR1AVPR1A | |
| SCHEMBL4936062 | 0.89 | OXTR (0.56) | AGTR2OXTRAGTR1AVPR1A | |
| SCHEMBL5744747 | 0.83 | OXTR (0.65) | OXTRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4940289 | 0.83 | OXTR (0.65) | OXTRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5744744 | 0.83 | OXTR (0.65) | OXTRALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4942106 | 0.80 | OXTR (0.51) | AGTR2OXTRALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | MERCK SERONO SA (CH) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171309-A1 | Pharmaceutically active pyrrolidine derivatives as bax inhibitors | SUCNR1, PYCR1, GLS | AGTR2 2446/4885OXTR 189/4885ALDH1A1 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.